For related articles and more information, please visit OCA’s Genetic Engineering page and our Millions Against Monsanto page.

The US Food & Drug Admin. just approved a drug made from genetically modified carrots to treat Gaucher, a rare disease found mostly among Ashkenazi Jews.  Out of a global population of 6.8 billion, an estimated range of 600,000 to a million people carry the recessive gene for it, though not all are symptomatic.

The incidence of Gaucher is so rare, in fact, that to approve a GMO carrot for this purpose makes no sense, raising the specter of some unstated plan.

As expected when humans ingest active foreign DNA, one of the side effects of the FDA-approved drug, Elelyso®, is anaphylactic shock, among other allergic reactions.

Gaucher develops in offspring of parents who both carry and pass on a recessive gene that prevents development of an enzyme that allows “harmful substances to build up in the liver, spleen, bones, and bone marrow,” explains the A.D.A.M. Medical Encyclopedia.  “The substances prevent cells and organs from working properly.”

The recessive gene only appears in 6-10 percent of Ashkenazi Jews, who number just over 10 million today.